Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
about
Safety and efficacy of fixed-dose heparin in carotid endarterectomyLow molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterizationHemodynamic and Hematologic Effects of Histotripsy of Free-Flowing Blood: Implications for Ultrasound-Mediated ThrombolysisClinical utilization of the international normalized ratio (INR).Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.Aspirin for primary prevention of cardiovascular events.Molecular mapping of the heparin-binding exosite of thrombin.Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.A review of the role of anticoagulation in the treatment of peripheral arterial disease.Controlled continuous systemic heparinization increases success rate of artery-only anastomosis replantation in single distal digit amputation: A retrospective cohort studyThe prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.Should all patients with dilated cardiomyopathy receive chronic anticoagulation?Novel antithrombotic therapy.Thrombosis and the pharmacology of antithrombotic agents.Oral vitamin K1: an option to reduce warfarin's activity.Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens.Periodontal implications: medically compromised patients.A new fluorescence "switch on" assay for heparin detection by using a functional ruthenium polypyridyl complex.Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.Changes in plasma warfarin levels and variations in steady-state prothrombin times.Description and Evaluation of the Implementation of a Weight-Based, Nurse-Driven Heparin Nomogram in a Tertiary Academic Medical Center.The use of the activated clotting time for monitoring heparin therapy in critically ill patients.Prevalence and descriptors of aspirin use as an antiplatelet agent in two New England communities.Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.Pharmacodynamics of warfarin in cats.Successful anticoagulation with dalteparin in a patient with mechanical heart valves.Selective Chromofluorogenic Sensing of Heparin by using Functionalised Silica Nanoparticles Containing Binding Sites and a Signalling Reporter
P2860
Q28343584-CB19BCBB-284D-43C3-8643-755A761DBD96Q28366163-73BCFAFD-F298-4A89-ACA9-249F036D9DB1Q30373340-679A4509-6582-4CFC-9E9B-EA9C718069B9Q33910636-570838A3-0BC6-48B6-8EBB-FD79A260E99BQ34450711-0E8EDF8E-1E2C-4C88-A2E9-C497DCE07FF6Q34752312-56D71EE0-9C83-453A-AC75-DE6ABDFC6355Q35478768-F04D2405-ACBE-459F-A7A3-B0D5B1A60736Q36449216-4C68A46C-210E-4095-BCF3-8CBA0554B2D5Q36627535-BC1F5C15-7596-46E7-A27C-299E4575B596Q37077911-91E03DD5-5F10-4BD2-B72F-2D9F7D539585Q37316352-E896D4C5-C41C-4193-84AD-25794F55628AQ37361505-1271BB97-8C7B-4375-98CC-D1B80A91366FQ40693723-09B07F35-DB4A-43AA-8A80-6EB381458B54Q40725160-7ABC54A2-244A-450D-BB7F-C2EF8D7404A7Q40938710-1AB8D363-00D3-4820-AB31-BF3E12C2E046Q41009859-F1A8B447-DCBA-41C9-953D-1D3DBCFE7516Q41142601-4C2A51B4-E046-4A34-ACF5-D10487D4AA99Q41387481-14E3362A-B4DB-43E3-A660-BF50C0DA4800Q41444849-8A072F7C-122E-4C7E-8656-31070618D224Q43418092-632A2DD1-B8A9-409F-8EC3-29DD02027739Q46202438-72AE2A21-9457-4D46-915C-DF5288A1D745Q46621937-AE580C1A-C5F1-45F2-BBAE-FC5A9298DC43Q47196181-D14772BB-9BD0-4BFE-905D-A79D6584FD02Q48384178-953BF524-5AA3-476F-9AA9-696428903DE6Q51057365-C119B0EC-E69B-4E87-89D9-EB7E2B15B603Q51541734-57E6A8FA-E6D2-4B5A-8CB8-42B368D96908Q52068750-2A81D446-7BD2-4144-ADF7-F38BD66664E9Q53341460-8C833968-B0C7-4175-B19E-5BC8BE144FFCQ57401221-28824AC2-4102-4559-B490-F33AE9738335
P2860
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@ast
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@en
type
label
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@ast
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@en
prefLabel
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@ast
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@en
P2093
P1433
P1476
Heparin: mechanism of action, ...... itoring, efficacy, and safety.
@en
P2093
P304
P356
10.1378/CHEST.102.4_SUPPLEMENT.337S
P407
P433
P577
1992-10-01T00:00:00Z